The announcement “Appendix 3Y — Change of Director’s Interest Notice” has been lodged with the Australian Securities Exchange.
Read Appendix 3Y — Change of Director’s Interest Notice.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce